Intarcia Therapeutics

February 26, 2020

Go or no go? Ozanimod and Fintepla await FDA verdicts

Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's Fintepla will be scrutinised.

Evaluate

US FDA approval tracker: March 2020

Go or no go? Ozanimod and Fintepla await FDA verdicts

The cash register rings for Biontech and ADC Therapeutics

Are small companies carrying the complete response letter can?

Venture financing still positive but big rounds less common

Healthcare unicorns and where to find them

With creativity it still makes sense to turn royalties into cash

Chasing ever bigger, ever fewer venture rounds

Oxford Nanopore squares up to Illumina's sequencing might

Biotech venture funding shrinks as post-boom shape emerges

Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers.

Latest Reports

H1 Round Up: The haves and the have-nots

ADA/EASL eBook

Editor's Picks

Astrazeneca and Daiichi’s big reveal disappoints

Pharma finds a way to gain weight

Protagonist investors flake as psoriasis pill disappoints

Approaching datasets for big pharma

Nkarta goes back to basics